Accurate, Stable, Efficient: Hzymes’ E. coli DNA Detection Kit Powers Biologic Drug Development from Process to Release

Background

With the rapid development of biotechnology, biologics such as monoclonal antibodies, recombinant proteins, gene therapies, and mRNA vaccines have become a cornerstone in safeguarding human health. During the research, development, and production of these innovative drugs, an efficient expression system is fundamental to achieving large-scale manufacturing. Among them, Escherichia coli (E. coli), with its clear genetic background, rapid growth, high expression yield, and low cultivation cost, has become the "main force" in prokaryotic expression systems. It is widely used in the production of recombinant proteins, vaccines, insulin, growth hormones, interferons, various enzyme preparations, and plasmid DNA.

Figure 1: Broad Applications of the E. coli Recombinant Expression System in Biopharmaceutical and Other Fields

However, while efficiently synthesizing target products using E. coli, the host cell's own biological components—such as host cell proteins (HCPs) and host cell DNA (HCD)—become major process-related impurities. If these residual impurities are not effectively removed by downstream purification processes, their presence in the final product may pose serious safety risks to the human body. In particular, residual host cell DNA may carry three major potential biological risks: immunogenicity, carcinogenicity, and infectivity.

Regulatory Standards

To ensure the safety of biologics, drug regulatory agencies worldwide have established strict limits for residual host cell DNA. These limits are generally based on risk assessments, taking into account different routes of administration (e.g., intravenous, subcutaneous) and dosage levels.

The U.S. Food and Drug Administration (FDA) currently recommends that residual DNA in the final product should not exceed 10 ng per dose. For biologics, the upper limit for host cell DNA residue is set at 100 pg per dose.

European Pharmacopoeia The general guidelines stipulate that residual DNA in biologics should not exceed 10 ng per dose.

Chinese Pharmacopoeia It clearly states that for biologics produced using cell substrates, the residual host DNA should be ≤100 pg/dose; for vaccines produced using bacterial or fungal substrates, the limit should be ≤10 ng/dose.

Regarding detection methods, the 2025 edition of the Chinese Pharmacopoeia further strengthens the requirements for detecting residual host cell DNA (HCD). The new version includes ADC drugs under regulation, adds detection requirements for various monoclonal antibody drugs and certain vaccines, and explicitly mandates the use of General Chapter 3407 Method III (qPCR) for HCD detection. This indicates that qPCR-based HCD detection will become the mainstream trend in the industry.

Table 1: Comparison of HCD Detection Requirements in 2025 vs 2020 Editions of the Chinese Pharmacopoeia

Solutions

Hzymes' E. coli Residual DNA Detection Kit (Catalog No.: HBP003503) and the accompanying Sample Pre-treatment Kit (Catalog No.: HBP003610), which adopt qPCR fluorescence probe technology and magnetic bead-based nucleic acid extraction, respectively, provide an accurate and efficient quality control solution for detecting E. coli residual DNA in biologics. These kits are applicable across all stages of biopharmaceutical development.

Figure 2: Manual/Automated Extraction + E. coli Residual DNA Detection Workflow

Applications

Process Development and Optimization

During strain screening, fermentation optimization, and downstream purification design, accurately monitoring E. coli DNA at each step helps guide process adjustments to minimize residual levels in the final product.

Raw Material Release

Used to evaluate whether raw and auxiliary materials (e.g., culture media, buffers) used in the production process are contaminated with E. coli DNA.

In-process and Final Product Release Testing

Serves as a critical quality control test for product release, ensuring the final product complies with regulatory residual DNA limits.

Introduction

Validated by multiple customers and various sample types, this product enables accurate, stable, and rapid fg-level quantification of HCD (host cell DNA) in biologics, intermediates, semi-finished, and finished drug products.

1. Host Cell Residual DNA Sample Pre-treatment Kit

Offers both manual and automated magnetic bead-based extraction options. Manual extraction takes 2 hours, while automated extraction requires only 1.5 hours (with <30 minutes of hands-on time), providing a simple and efficient workflow.

2. E. coli Residual DNA Detection Kit

Calibrated with the national DNA reference standard and utilizes pharmacopoeia-listed primer-probe sequences. Directly aligned with regulatory requirements, saving customers time and effort by eliminating the need for additional method validation.

Features

Quantitative Accuracy

Calibrated using the national DNA reference standard; pharmacopoeia-compliant primers and probes help achieve more precise quantification.

Stable Results

The sample pre-treatment kit has been validated with a wide variety of sample types, including recombinant proteins, vaccines, antibody drugs, and plasmid DNA. Spike-recovery rates are consistently stable between 70% and 130%.

Easy Operation

Offers both manual and automated extraction options for user convenience, helping reduce labor and time costs.

High-Quality Service

Flexible matching solutions are available to meet user needs, backed by responsive technical support.

Data

Linearity Range

The product offers a wide linear range from 30 fg/μL to 300 pg/μL, with R² = 1.000 and an amplification efficiency of 98.22%. The coefficient of variation (CV) at all concentrations is less than 15%.

E. coli Standard Curve Amplification Plot

Accuracy

Hzymes' E. coli DNA standards are calibrated against the national DNA reference standard, with a purity of 100%. qPCR-determined concentrations show RSD <5% compared to the national standard. Primers and probes match pharmacopoeial sequences, precisely meeting regulatory expectations.

Figure 4: Electrophoresis of Hzymes E. coli DNA Standards vs National Standard

Table 2: qPCR Quantification Results of Hzymes E. coli DNA Standards vs National Standard

Spike Recovery Rate

Validated across multiple customers and diverse sample types, the kit is compatible with recombinant proteins, enzyme preparations, plasmid DNA, and other sample categories for E. coli HCD detection. The spike recovery rate remains consistently between 70% and 130%.

Limit of Quantification and Precision

The kit provides a consistent limit of quantification (LOQ) down to 30 fg/μL. Precision testing shows that results from different operators have a CV of less than 15%, ensuring high experimental credibility and reproducibility.

Figure 6: Amplification Curve at 30 fg/μL Limit of Quantification

Specificity

The product demonstrates high specificity, capable of specifically detecting E. coli DNA without cross-reactivity from other common host cell DNA sources.

Cross-Reactivity Test with Different Genomic DNAs

Stability

The kit maintains performance after accelerated thermal aging for 14 days at 37°C and after five freeze-thaw cycles, showing no loss in functionality. Storage and transportation are thus worry-free. Inter-lot consistency tests further demonstrate stable and uniform product performance.Table 4: Stability under 37°C Heat Acceleration and Freeze-Thaw Conditions

Figure 8: Amplification Curves of Different Kit Lots